Editas Medicine, Inc. Common Stock
Here’s whether Editas Medicine, Inc. Common Stock (EDIT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 65 — healthy momentum range; strong 1-year return of +13.9%; 3-month momentum positive (+12.7%); rising volume confirms the move (1.44x 30d avg). Currently 31.5% off its 52-week high. Score: +7/7.
EDIT is in a confirmed uptrend, trading above both its 50-day ($2.91) and 200-day ($2.59) moving averages. An RSI of 64.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +13.9% compares to +20.5% for SPY (trailed the market by 6.6%). The current 31.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.